NASDAQ : IMVT

Immunovant, Inc.

$40.09 USD

$0.68 (1.73%)

Volume
884.92K
Average Volume
1.78M
Market Capitalization
$8.23B
P/E Ratio
-14.42
Dividend Yield
0.00%
Price Target
$40.00
Year High
$41.23
Year Low
$14.32
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$9.09
Company Overview

NASDAQ

Eric Venker

Biotechnology

Healthcare

IMVT

315

US

USD

https://immunovant.com

917 580 3099

45258J102

0001764013

Liquidity Metrics

0.00

9.09

9.09

8.64

0.00

Sales & Valuation

-$

0.00

9.58

-20.21

-2.00

Profitability

-$2.77

-$505.61M

0.00%

0.00%

-68.16%

-52.83%

P/E Metrics

-14.42

7.27

7.27

Analyst Price Target & Rating

$40.00

$40.00

$40.00

Sell

2/5

23 Analysts

0.23%

Financial Health Scores

43.25

1/9

$844.4M

$957.01M

$104.42M

-$505.39M

Key Metrics (TTM)

$7.19B

0.00

-14.24

9.09

-68.16%

-62.50%

-6.30%

-5.03%

-13361 days

Company Executives
Name Title
Lorna Liganor Senior Vice President of Clinical Operations
Becky Merlina Senior VP & Global Head of Quality
Luciano Pollastrini Senior Vice President of CMC Technical Operations
Khira Gabliani Chief of Staff to the CEO
Andy Deig Senior Vice President of Strategic Finance
Eric Venker Chief Executive Officer & Director
Yan Zheng Senior Vice President of Biostatistics, Programming & Data Management
Christine Blodgett Senior Vice President of Human Resources
Ruby Grewal Senior Vice President of Commercial
Julie Kirschling Senior Vice President of Program & Alliance Management
Melanie Gloria Chief Operating Officer
Sheetal Patel Senior Vice President of Clinical Development
Jay S. Stout Chief Technology Officer
Christopher Van Tuyl Chief Legal Officer & Corporate Secretary
Frank Torti Executive Chairperson of the Board
Tiago Girao Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidi ... ary under the umbrella of Roivant Sciences Ltd.

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

2026-07-27 23:09:59

I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

2026-07-20 17:08:00

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

2026-06-19 12:31:17

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

Immunovant Stock Gains 12.4% in a Month: What's Driving It?

2026-06-12 11:11:00

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

2026-05-25 06:27:31

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

2026-05-21 13:09:35

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

2026-05-21 12:07:14

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

2026-05-21 10:20:56

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.

Frequently Asked Questions

What is the current Immunovant, Inc. (IMVT) stock price?

Immunovant, Inc.(NASDAQ:IMVT) stock price is $40.09 in the last trading session. During the trading session, IMVT stock reached the peak price of $41.23 while $14.32 was the lowest point it dropped to. The percentage change in IMVT stock occurred in the recent session was 1.73% while the dollar amount for the price change in IMVT stock was $0.68.

IMVT's industry and sector of operation?

The NASDAQ listed IMVT is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of IMVT?

Lorna Liganor | Senior Vice President of Clinical Operations
Becky Merlina | Senior VP & Global Head of Quality
Luciano Pollastrini | Senior Vice President of CMC Technical Operations
Khira Gabliani | Chief of Staff to the CEO
Andy Deig | Senior Vice President of Strategic Finance

How many employees does IMVT have?

Number of IMVT employees currently stands at 315. IMVT operates from 320 West 37th Street, Durham, NY 10018, US.

Link for IMVT official website?

Official Website of IMVT is: https://immunovant.com

How do I contact IMVT?

IMVT could be contacted at phone #917 580 3099 and can also be accessed through its website. IMVT operates from 320 West 37th Street, Durham, NY 10018, US.

How many shares of IMVT are traded daily?

The average number of IMVT shares traded daily for last 3 months was 1.78M.

What is the market cap of IMVT currently?

The market value of IMVT currently stands at $8.23B with its latest stock price at $40.09